Scholarlink

Purpose <p>Evaluating the impact for different number of Anti-vascular endothelial growth Factor (VEGF) injections on macular neovascularization (MNV) secondary to pathological myopia, during a 2-year follow-up period, in relation to visual outcome.</p> Methods <p>This was a multicenter, retrospective study of patients with myopic MNV (mMNV) for 24 months.</p> Results <p>A total of 55 patients with mMNV, with a mean age of 65.7 ± 14.5 years, met the inclusion criteria. The mean number of injections was significantly higher during the first year of follow-up with 8.78 ± 2.90 within the 1st year versus 3.45 ± 4.40 during the 2nd year (<i>p</i> = 0.037). Visual acuity (VA) remained relatively stable throughout the follow-up (<i>p</i> = 0.902), with most patients maintaining their vision or experiencing a loss of up to 5 Snellen letters. (42 patients, 76.3%, <i>p</i> &lt; 0.001).</p> Conclusion <p>During a 24-month period, there was a lack of BCVA improvement, which may be attributed to the PRN injection regimen and the relatively low number of injections administered for mMNV. These findings suggest that mMNV may be undertreated in routine practice, with suboptimal intravitreal injection frequency.</p> Key messages <p><Emphasis Type="BoldItalic">What is known</Emphasis><UnorderedList Mark="Bullet"> <ItemContent> <p>The PRN injection regimen is widely used for treating myopic macular neovascularization (mMNV) due to its less aggressive nature and the potential risks of retinal break, retinal detachment, and other complications in highly myopic eyes.</p> </ItemContent> </UnorderedList></p> <p><Emphasis Type="BoldItalic">What is new</Emphasis><UnorderedList Mark="Bullet"> <ItemContent> <p>At the 24-month follow-up, patients with mMNV treated with anti-VEGF agents in a PRN regimen showed no significant improvement in BCVA.</p> </ItemContent> <ItemContent> <p>Myopic MNV may be fallacy thought of as a less aggressive pathology and therefore is undertreated and perhaps may require a much more intensive injection schedule.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Myopic macular neovascularization treatment: A 2-year follow-up of a real-life cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月26日

查看全文
  • Assaf Hilely,
  • Roee Arnon,
  • Reut Shor,
  • Ori Segal,
  • Justin Lerann Shad,
  • Eran Greenbaum,
  • Omer Trivizki,
  • Anat Loewenstein,
  • Gilad Rabina

摘要

Purpose

Evaluating the impact for different number of Anti-vascular endothelial growth Factor (VEGF) injections on macular neovascularization (MNV) secondary to pathological myopia, during a 2-year follow-up period, in relation to visual outcome.

Methods

This was a multicenter, retrospective study of patients with myopic MNV (mMNV) for 24 months.

Results

A total of 55 patients with mMNV, with a mean age of 65.7 ± 14.5 years, met the inclusion criteria. The mean number of injections was significantly higher during the first year of follow-up with 8.78 ± 2.90 within the 1st year versus 3.45 ± 4.40 during the 2nd year (p = 0.037). Visual acuity (VA) remained relatively stable throughout the follow-up (p = 0.902), with most patients maintaining their vision or experiencing a loss of up to 5 Snellen letters. (42 patients, 76.3%, p < 0.001).

Conclusion

During a 24-month period, there was a lack of BCVA improvement, which may be attributed to the PRN injection regimen and the relatively low number of injections administered for mMNV. These findings suggest that mMNV may be undertreated in routine practice, with suboptimal intravitreal injection frequency.

Key messages

What is known

The PRN injection regimen is widely used for treating myopic macular neovascularization (mMNV) due to its less aggressive nature and the potential risks of retinal break, retinal detachment, and other complications in highly myopic eyes.

What is new

At the 24-month follow-up, patients with mMNV treated with anti-VEGF agents in a PRN regimen showed no significant improvement in BCVA.

Myopic MNV may be fallacy thought of as a less aggressive pathology and therefore is undertreated and perhaps may require a much more intensive injection schedule.